0.81
+0.0034(+0.42%)
Currency In USD
Address
333 Twin Dolphin Drive
Redwood City, CA 94065
United States of America
Phone
650 649 3530
Website
Sector
Healthcare
Industry
Biotechnology
Employees
228
First IPO Date
November 06, 2014
| Name | Title | Pay | Year Born |
| Mr. Dennis M. Lanfear | Chairman, President & Chief Executive Officer | 1.93M | 1955 |
| Mr. Bryan J. McMichael | Chief Financial Officer | 712,095 | 1979 |
| Mr. Michael Chen | Senior Vice President of Commercial Analytics & Trade | 0 | N/A |
| Ms. Jodi Sievers | Vice President of Investor Relations & Corporate Communications | 0 | N/A |
| Mr. Andy Rittenberg | Executive Vice President of General Counsel | 0 | N/A |
| Mr. Richard L. Hameister | Chief Technical Officer | 0 | N/A |
| Mr. Scott Saywell | Executive Vice President of Corporate Development | 0 | N/A |
| Dr. Rosh Dias M.D., MRCP | Chief Medical Officer | 0 | 1969 |
| Ms. Rebecca Sunshine | Chief Human Resources Officer | 0 | 1963 |
| Dr. Theresa M. Lavallee Ph.D. | Chief Development Officer & Chairman of Scientific Advisory Board | 0 | 1966 |
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
